Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
7,533
archived clinical trials in
Chronic Obstructive Pulmonary Disease

Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01340 Boehringer Ingelheim Investigational Site
mi
from
Anderson, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01340 Boehringer Ingelheim Investigational Site
mi
from
Anderson, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Charleston, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01056 Boehringer Ingelheim Investigational Site
mi
from
Chester, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01056 Boehringer Ingelheim Investigational Site
mi
from
Chester, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1182.58.01 Boehringer Ingelheim Investigational Site
mi
from
Columbia, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1182.58.01 Boehringer Ingelheim Investigational Site
mi
from
Columbia, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1268.17.01031 Boehringer Ingelheim Investigational Site
mi
from
Easley, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1268.17.01031 Boehringer Ingelheim Investigational Site
mi
from
Easley, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01259 Boehringer Ingelheim Investigational Site
mi
from
Florence, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01259 Boehringer Ingelheim Investigational Site
mi
from
Florence, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01013 Boehringer Ingelheim Investigational Site
mi
from
Gaffney, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01013 Boehringer Ingelheim Investigational Site
mi
from
Gaffney, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Greenville, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01295 Boehringer Ingelheim Investigational Site
mi
from
Greenwood, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01295 Boehringer Ingelheim Investigational Site
mi
from
Greenwood, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01093 Boehringer Ingelheim Investigational Site
mi
from
Greer, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01093 Boehringer Ingelheim Investigational Site
mi
from
Greer, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01335 Boehringer Ingelheim Investigational Site
mi
from
Myrtle Beach, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01335 Boehringer Ingelheim Investigational Site
mi
from
Myrtle Beach, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Spartanburg, SC
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01004 Boehringer Ingelheim Investigational Site
mi
from
Rapid City, SD
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01004 Boehringer Ingelheim Investigational Site
mi
from
Rapid City, SD
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01126 Boehringer Ingelheim Investigational Site
mi
from
Brentwood, TN
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01126 Boehringer Ingelheim Investigational Site
mi
from
Brentwood, TN
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1199.15.10006 Boehringer Ingelheim Investigational Site
mi
from
Chattanooga, TN
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1199.15.10006 Boehringer Ingelheim Investigational Site
mi
from
Chattanooga, TN
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01342 Boehringer Ingelheim Investigational Site
mi
from
Kingsport, TN
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01342 Boehringer Ingelheim Investigational Site
mi
from
Kingsport, TN
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1218.64.10009 Boehringer Ingelheim Investigational Site
mi
from
Arlington, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1218.64.10009 Boehringer Ingelheim Investigational Site
mi
from
Arlington, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01050 Boehringer Ingelheim Investigational Site
mi
from
Corsicana, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01050 Boehringer Ingelheim Investigational Site
mi
from
Corsicana, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Dallas, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1199.15.10110 Boehringer Ingelheim Investigational Site
mi
from
Fort Worth, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1199.15.10110 Boehringer Ingelheim Investigational Site
mi
from
Fort Worth, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Houston, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01274 Boehringer Ingelheim Investigational Site
mi
from
Longview, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01274 Boehringer Ingelheim Investigational Site
mi
from
Longview, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01116 Boehringer Ingelheim Investigational Site
mi
from
McKinney, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01116 Boehringer Ingelheim Investigational Site
mi
from
McKinney, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01262 Boehringer Ingelheim Investigational Site
mi
from
Richardson, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01262 Boehringer Ingelheim Investigational Site
mi
from
Richardson, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
San Antonio, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1218.61.01003 Boehringer Ingelheim Investigational Site
mi
from
Sugar Land, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1218.61.01003 Boehringer Ingelheim Investigational Site
mi
from
Sugar Land, TX
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01223 Boehringer Ingelheim Investigational Site
mi
from
Midvale, UT
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01223 Boehringer Ingelheim Investigational Site
mi
from
Midvale, UT
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01001 Boehringer Ingelheim Investigational Site
mi
from
Salt Lake City, UT
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01001 Boehringer Ingelheim Investigational Site
mi
from
Salt Lake City, UT
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01079 Boehringer Ingelheim Investigational Site
mi
from
Abingdon, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01079 Boehringer Ingelheim Investigational Site
mi
from
Abingdon, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01234 Boehringer Ingelheim Investigational Site
mi
from
Alexandria, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01234 Boehringer Ingelheim Investigational Site
mi
from
Alexandria, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01285 Boehringer Ingelheim Investigational Site
mi
from
Danville, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01285 Boehringer Ingelheim Investigational Site
mi
from
Danville, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01045 Boehringer Ingelheim Investigational Site
mi
from
Petersburg, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01045 Boehringer Ingelheim Investigational Site
mi
from
Petersburg, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01030 Boehringer Ingelheim Investigational Site
mi
from
Lynchburg, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01030 Boehringer Ingelheim Investigational Site
mi
from
Lynchburg, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
Boehringer Ingelheim Investigational Site
mi
from
Richmond, VA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01099 Boehringer Ingelheim Investigational Site
mi
from
Selah, WA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01099 Boehringer Ingelheim Investigational Site
mi
from
Selah, WA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1199.14.1259 Boehringer Ingelheim Investigational Site
mi
from
Spokane, WA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1218.64.10010 Boehringer Ingelheim Investigational Site
mi
from
Tacoma, WA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
1200.75.10024 Boehringer Ingelheim Investigational Site
mi
from
Wenatchee, WA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
1200.75.10024 Boehringer Ingelheim Investigational Site
mi
from
Wenatchee, WA
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01201 Boehringer Ingelheim Investigational Site
mi
from
Oregon, WI
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01201 Boehringer Ingelheim Investigational Site
mi
from
Oregon, WI
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
205.452.01344 Boehringer Ingelheim Investigational Site
mi
from
West Allis, WI
Comparison of Tiotropium in the HandhiHaler Versus the Respimat in Chronic Obstructive Pulmonary Disease
A Randomized, Active-controlled, Double-blind, Double-dummy, Parallel Group Design, Multi-center Trial to Compare the Efficacy and Safety of 2.5 µg and 5 µg Tiotropium Inhalation Solution Delivered by the Respimat Inhaler With Tiotropium Inhalation Capsules 18 µg Delivered by the HandiHaler
Status: Archived
Updated: 1/1/1970
205.452.01344 Boehringer Ingelheim Investigational Site
mi
from
West Allis, WI
IVR-Enhanced Care Transition Support for Complex Patients
E-Coaching: IVR-Enhanced Care Transition Support for Complex Patients
Status: Archived
University of Alabama - Burmingham
mi
from
Birmingham, AL
IVR-Enhanced Care Transition Support for Complex Patients
E-Coaching: IVR-Enhanced Care Transition Support for Complex Patients
Status: Archived
Updated: 1/1/1970
University of Alabama - Burmingham
mi
from
Birmingham, AL
Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease(COPD): Aim 1
Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in COPD: Aim 1
Status: Archived
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in Chronic Obstructive Pulmonary Disease(COPD): Aim 1
Eicosapentaenoic Acid and Protein Modulation to Induce Anabolism in COPD: Aim 1
Status: Archived
Updated: 1/1/1970
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Providence Western Washington Oncology
mi
from
Lacey, WA
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Providence Western Washington Oncology
mi
from
Lacey, WA
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Miami, FL
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Miami, FL
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Ann Arbor, MI
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Ann Arbor, MI
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Rochester, MN
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Rochester, MN
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
University of Chicago
mi
from
Chicago, IL
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
University of Chicago
mi
from
Chicago, IL
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Chesapeake Clinical Research, Inc
mi
from
Baltimore, MD
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Chesapeake Clinical Research, Inc
mi
from
Baltimore, MD
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
High Point, NC
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
High Point, NC
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Novartis Investigative Site
mi
from
Cincinatti, OH
A Study to Assess the Efficacy, Safety and Tolerability of Once-daily QVA149 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Status: Archived
Updated: 1/1/1970
Novartis Investigative Site
mi
from
Cincinatti, OH